USA – CoreMap, a Burlington, Vt.-based developer of a cure for atrial fibrillation (AF), raised $3m in Series A financing concurrently with a $20 million Series B financing.
The financing includes a diverse group of strategic, institutional, venture and individual partners including Qure Ventures and Russ Scully of The Fund at Hula. The financing will be used to accelerate the company’s ongoing product development efforts and initiate clinical outcome studies. Founded in 2016, CoreMap is advancing a cure for atrial fibrillation (AF) based on technology aimed at identifying the drivers of complex arrhythmias which will in turn unlock patient specific treatment options for those suffering from AF or any complex arrhythmia. CoreMap’s patented electrode design and configuration, combined with algorithmically driven mapping and visualization technology, will enable electrophysiologists to make more informed, patient specific therapeutic decisions to improve outcomes.The CoreMap System comprising the InvenioTM catheter and VidereXTM workstation are aimed at identifying the drivers of a patient’s arrhythmia, which will in turn unlock unique, electrically guided treatment options for individuals suffering from AF or any complex arrhythmia.10/02/2022
